Cannabis Science and Therapeutics: An Overview for Clinicians DOI
Leah Sera,

Carrie Hempel‐Sanderoff

The Journal of Clinical Pharmacology, Journal Year: 2023, Volume and Issue: 64(5), P. 499 - 513

Published: Dec. 25, 2023

Cannabis-based therapeutics have garnered increasing attention in recent years as patients seek alternative treatments for various medical conditions. This narrative review provides a comprehensive overview of the science behind use cannabis, focusing on evidence commonly treated In addition, addresses practical considerations using cannabis therapeutic agent, offering insights into dosing strategies, variations cannabinoid formulation, and individual patient responses. Precautions, adverse consequences, drug interactions are also discussed, with focus safety potential risks associated use.

Language: Английский

Therapeutic potential of CBD in Autism Spectrum Disorder DOI
João Francisco Cordeiro Pedrazzi, Lucas Hassib, Frederico Rogério Ferreira

et al.

International review of neurobiology, Journal Year: 2024, Volume and Issue: unknown, P. 149 - 203

Published: Jan. 1, 2024

Language: Английский

Citations

5
Cannabinoid Pharmaceutical Science: Laying the Foundation for Cannabis Therapeutics DOI
Leah Sera,

Carrie Hempel‐Sanderoff

Published: Jan. 1, 2025

Language: Английский

Citations

0
Epidemiology and Health Impacts of Substance Use DOI
Richard Alecsander Reichert, Flávia Zacouteguy Boos, Fernanda Machado Lopes

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Challenges of Extracting and Determining Cannabinoids in Different Matrices DOI
Janis Vella Szijj

Cannabis and Cannabinoid Research, Journal Year: 2024, Volume and Issue: 9(6), P. 1470 - 1477

Published: Aug. 13, 2024

Introduction: Accurate and precise analysis of cannabinoids is important for elucidating their therapeutic potential developing therapies, which are targeted toward different medical conditions. A wide range cannabis products present on the market available in dosage forms, including dried flowers, extracts, consumables. The aim this article to provide an updated narrative review literature challenges analyzing plant material, oils, edibles.

Language: Английский

Citations

3
Effects of Water and Wind Stress on Phytochemical Diversity, Cannabinoid Composition, and Arthropod Diversity in Hemp DOI Creative Commons
Elma Kay, Casey S. Philbin, Lora A. Richards

et al.

Plants, Journal Year: 2025, Volume and Issue: 14(3), P. 474 - 474

Published: Feb. 5, 2025

Phytochemical diversity is increasingly appreciated as an important attribute of plants that affects their interactions with other organisms and can have substantial effects on arthropod communities, but this axis less studied for agricultural plants. For both managed natural systems, understanding how extreme weather events, such droughts, floods, wind, affect phytochemical part predicting responses plant–arthropod to climate change. In outdoor field experiment two distinct varieties hemp (Cannabis sativa L., Cannabaceae), we investigated the simulated water stress from reduced availability flooding, along unplanned wind event cannabinoid profiles. We also examined changes in chemistry affected associated arthropods. Our results indicate genetic variety environmental variation composition, these cascaded alter communities flowers. The largest differences were found between different varieties, which accounted over 10% diversity. Stress floods flowers, had negative cannabidiol (CBD) concentrations, deficit flooding caused subtle shifts composition. subsequent cascading depended it was characterized, increases CBD causing higher richness, while increased These provide insights into potential chemistry, well consequences colonizing

Language: Английский

Citations

0
Beyond Cannabidiol: The Contribution of Cannabis sativa Phytocomplex to Skin Anti-Inflammatory Activity in Human Skin Keratinocytes DOI Creative Commons
Marco Fumagalli, Giulia Martinelli,

Giuseppe Paladino

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 647 - 647

Published: April 28, 2025

Background: Cannabis sativa L. (C. sativa) has a long history of medicinal use. Its inflorescences contain bioactive compounds like non-psychotropic cannabidiol (CBD), which is well known for its anti-inflammatory potential in skin conditions such as psoriasis, and psychotropic Δ-9-tetrahydrocannabinol (THC). Keratinocytes, the main cells epidermis, are crucial regulating inflammation by producing mediators IL-8 when stimulated agents TNFα. Methods: This study explores effects standardized C. extract (CSE) with 5% CBD less than 0.2% THC human keratinocytes challenged The aim this to analyze specific contributions constituents CSE inflammatory responses fractionating examining individual components. Results: MTT assays showed that was non-toxic HaCaT up 50 μg/mL. inhibited NF-κB activity reduced secretion concentration-dependent manner, mean IC50 values 28.94 ± 10.40 μg/mL 20.06 2.78 (mean SEM), respectively. Fractionation into four subfractions revealed more lipophilic fractions (A B) were most effective inhibiting NF-κB, indicating cannabinoids cannflavins key contributors. Pure one active reducing NF-κB-driven transcription (together cannabigerol), due abundance CSE, it primarily responsible activity. Conclusions: highlights CBD’s significant role underscores need consider synergistic interactions several molecules within extracts maximum efficacy. Standardized essential reproducible results variability responses.

Language: Английский

Citations

0
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence DOI Creative Commons
Michael T. Lynskey, Alkyoni Athanasiou‐Fragkouli, Hannah Thurgur

et al.

BJPsych Open, Journal Year: 2024, Volume and Issue: 10(2)

Published: March 1, 2024

Background Cannabis-based medicinal products (CBMPs) are increasingly being used to treat post-traumatic stress disorder (PTSD), despite limited evidence of their efficacy. PTSD is often comorbid with major depression, and little known about whether depression alters the effectiveness CBMPs. Aims To document prevalence among individuals seeking CBMPs examine varies by status. Method Data were available for 238 people CBMP treatment (5.9% treatment-seeking sample) 3-month follow-up data 116 these. Self-reported symptoms assessed at entry using Checklist – Civilian Version (PCL-C). The probable presence was nine-item Patient Health Questionnaire (PHQ-9). Additional included sociodemographic characteristics self-reported quality life. Results In total, 77% met screening criteria which associated higher levels symptomatology (mean 67.8 v. 48.4, F (1,236) = 118.5, P < 0.001) poorer general health, life sleep. reduced substantially 3 months after commencing 58.0 47.0, (1,112) 14.5, 0.001), a significant interaction ( 6.2, 0.05) indicating greater improvement in those difference 15.3) than without 7). Conclusions Depression common symptom severity Effectiveness treating does not appear be impaired depression.

Language: Английский

Citations

2
Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review DOI Creative Commons
João Luís Q. Simei, José Diogo R. Souza, João Francisco Cordeiro Pedrazzi

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1644 - 1644

Published: Dec. 6, 2024

Background: Emerging evidence supports cannabidiol (CBD) as a promising therapeutic compound for various health conditions, despite its approval medication (product medical purposes) remaining restricted to limited range of clinical indications. Simultaneously, the regulation cannabis-derived products medicinal and recreational use has expanded their global market availability meet local community demands. This scenario presents complex challenge clinicians, researchers, industry, appeal uses CBD is growing more rapidly than scientific supporting safety effectiveness. Outcomes: A narrative review was conducted discuss best regarding pharmacological profile CBD, efficacy, within context perspectives on development new cannabinoid-based drugs. Key articles addressing facets this issue were selected comprehensive analysis. Conclusions: Clinicians researchers may face unique challenges in understanding prospects developing indications, given heterogeneity terminologies quality composition cannabis-based available market. More basic research that complies with regulatory agencies’ testing guidelines, such good manufacturing practices (GMPs), laboratory (GLPs), (GCPs), needed obtain or any other cannabinoid broader

Language: Английский

Citations

2
Cannabidiol in anxiety disorders: Current and future perspectives DOI
João Luís Q. Simei, José Diogo R. Souza,

João Roberto Lisboa

et al.

International review of neurobiology, Journal Year: 2024, Volume and Issue: unknown, P. 205 - 234

Published: Jan. 1, 2024

Language: Английский

Citations

1
Cannabis Science and Therapeutics: An Overview for Clinicians DOI
Leah Sera,

Carrie Hempel‐Sanderoff

The Journal of Clinical Pharmacology, Journal Year: 2023, Volume and Issue: 64(5), P. 499 - 513

Published: Dec. 25, 2023

Cannabis-based therapeutics have garnered increasing attention in recent years as patients seek alternative treatments for various medical conditions. This narrative review provides a comprehensive overview of the science behind use cannabis, focusing on evidence commonly treated In addition, addresses practical considerations using cannabis therapeutic agent, offering insights into dosing strategies, variations cannabinoid formulation, and individual patient responses. Precautions, adverse consequences, drug interactions are also discussed, with focus safety potential risks associated use.

Language: Английский

Citations

3